Biovac

SAHPRA-Licensed Vaccine Manufacturer

Engineering the Future of Africa's Health Security

Pioneering vaccine manufacturing to protect life, strengthen pandemic resilience, and position Africa at the forefront of biopharmaceutical innovation.

Explore Our Mission View Pipeline

SAHPRA Licensed• WHO PQ Aligned• PIC/S GMP• AU Agenda 2063• Pfizer Technology Transfer• mRNA Hub Partner• 9-DFI Consortium Backed•

Continental Impact

Anchoring Africa's Vaccine Future

Strategic milestones aligned with the AU Agenda 2063, South Africa's NDP 2030, and the Partnership for African Vaccine Manufacturing (PAVM) 60% by 2040 target.

Target Annual Capacity

New multi-vaccine plant expansion from current 150M doses

African Self-Sufficiency Target

0% by 2040

AU PAVM continental manufacturing target

Doses Delivered Since 2003

0M+

Across SA, Angola, Botswana, Eswatini, Lesotho, Mozambique, Namibia

Our Vision

Transforming Healthcare Through African Innovation

We're building Africa's most advanced vaccine manufacturing ecosystem, combining cutting-edge technology with South Africa's strategic vision to create a self-sufficient continental vaccine supply.

Vaccine Independence

Achieving 70% vaccine self-sufficiency by 2030 through localized production.

Innovation Leadership

Establishing South Africa as the continent's vaccine manufacturing innovation hub.

Clinical Pipeline

Therapeutic Development Pipeline

Active programs spanning oncology, infectious disease, and rare disease across clinical phases.

Active

Enrolling

Planning

Candidate

Target

Phase

Status

Progress

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Our Science

Molecular Innovation Platform

From computational discovery to GMP manufacturing, our integrated platform accelerates the journey from molecule to medicine.

Discovery Phase

Proprietary mRNA Platform

Our computational biology pipeline leverages AI-driven antigen selection to identify optimal mRNA sequences. Modified nucleosides ensure enhanced translational efficiency and reduced innate immunogenicity.

4,200+

Candidates screened

72hrs

Design-to-construct

Formulation Phase

Lipid Nanoparticle Delivery

Ionizable lipid nanoparticles encapsulate mRNA cargo with >95% encapsulation efficiency. Proprietary PEGylation chemistry ensures optimal biodistribution and cellular uptake in target antigen-presenting cells.

95.2%

Encapsulation rate

80nm

Mean particle size

Scale-Up Phase

GMP Manufacturing at Scale

Continuous-flow microfluidic mixing enables seamless transition from bench to commercial scale. Single-use bioreactor systems ensure batch-to-batch consistency while minimizing cross-contamination risk.

200K L

Bioreactor capacity

500M

Annual doses

Manufacturing Infrastructure

Continental Manufacturing Capacity

SAHPRA-licensed, GMP-compliant vaccine manufacturing infrastructure engineered for continental self-sufficiency.

150M

Annual Dose Capacity

Current installed capacity across fill-finish and drug substance platforms

500M

Annual Dose Output

Fill-finish and lyophilization across multiple vaccine formats

ISO 5

Cleanroom Classification

Class 100 equivalent with continuous environmental monitoring

BSL-3

Biosafety Level

Full containment capability for pathogen handling and viral vector production

GMP Certifications

SAHPRA GMP Compliance
FDA cGMP Aligned
EMA Annex 1 Referenced
WHO Prequalification Pathway

Technology Platforms

mRNA / Modified Nucleoside
Viral Vector (AAV, Adenovirus)
Recombinant Protein Expression
Monoclonal Antibody (CHO)

Quality Systems

Real-time PAT Analytics
HPLC / Mass Spectrometry
Electronic Batch Records
Cold Chain (-70°C to +8°C)

Strategic Partnering

The African Vaccine Manufacturing Advantage

South Africa's strategic position as the continent's most advanced pharmaceutical economy, combined with 9-DFI consortium backing and SAHPRA regulatory alignment, creates an unparalleled vaccine manufacturing investment thesis.

Direct market access to 1.4B+ population across the African continent

DFI-backed funding with NDP 2030 industrial policy alignment

Accelerated SAHPRA regulatory pathway for domestic manufacturers

Technology transfer agreements with global pharma leaders

Explore Partnership

560M

Continental Dose Target by 2040

1.4B+

Continental Population Served

400+

Employees & Growing

60%